In the 2025 financial year, Datwyler generated revenue of CHF 1'100.5 million. Adjusted for negative currency effects of -3.7%, the company achieved organic growth of 3.1%. Due to these currency effects, reported revenue was overall 0.6% below the prior-year level.

Datwyler expanded its NeoFlex™ range of fully coated plungers with a solution for large-volume cartridges containing 20mL. The launch responds to rising demand for on-body devices for subcutaneous (SC) delivery of biotherapeutics to patients seeking convenient at-home care.

Datwyler announced a collaboration with LTS Device Technologies, a developer of smart wearable devices for drug delivery, and Stevanato Group

Datwyler gained momentum in the first half of 2025 despite a challenging environment.

Datwyler announces the expansion of its NeoFlex™ range of coated plungers with new sizes for containers aimed at large-volume auto-injectors and wearable devices.

Datwyler will deliver RTU components in robust packaging guaranteeing a shelf life of 2 years after steam sterilization.

Datwyler sponsors deployment of AquaTower Filtration Systems to combat contamination of drinking water as part of company’s commitment to communities surrounding Pune, India operation.

Datwyler is now focusing exclusively on system-critical elastomer components. The continuing operations generated record revenue and currency-adjusted growth of 15.0%.

Datwyler is expanding its production capacity with targeted investments and laying the foundation for further profitable growth.

Despite the ongoing uncertainty caused by the pandemic, Datwyler has increased its forecasts for the year as a whole for revenue and EBIT margin to over CHF 1’150 million and above 16%, respectively.

The company will also showcase NeoFlex™ plungers and DuraCoat™ combiseals, which enable drug developers to protect the integrity of injectables throughout development to distribution.

Unveiled at Pharmapack, the no-added silicone sealing solution mitigates contamination threats